Vault Bioventures’ Post

Johnson & Johnson's seltorexant significantly improved depression and insomnia in a phase 3 trial. This breakthrough drug, used with existing antidepressants, met all primary and secondary endpoints in a study of 588 patients. Impact - Potentially a game-changer for treating depression with insomnia, addressing a major unmet need. Insights - ▪️ Highlights the crucial link between depression and sleep. ▪️ Demonstrates strong efficacy and safety. Questions - ▪️ How will seltorexant reshape MDD treatment? ▪️ What further research is needed? #MentalHealth #Depression #Insomnia #ClinicalTrials

J&J's daily add-on pill improves depression and insomnia symptoms, acing phase 3

J&J's daily add-on pill improves depression and insomnia symptoms, acing phase 3

fiercebiotech.com

To view or add a comment, sign in

Explore topics